Park West Asset Management’s Starling Oncology Warrant STLNW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
– Sell
-62,200
Closed -$43K – 108
2021
Q4
$43K Hold
62,200
– – ﹤0.01% 147
2021
Q3
$87K Hold
62,200
– – ﹤0.01% 158
2021
Q2
$108K Hold
62,200
– – ﹤0.01% 171
2021
Q1
$84K Buy
+62,200
New +$115K ﹤0.01% 171

Other funds holding STLNW

Park West Asset Management's STLNW Position: Q1 2022 in Review

Park West Asset Management sold out of Starling Oncology Warrant (STLNW) in Q1 2022, closing a stake of 62,200 shares — an estimated $43K sold.

Park West Asset Management first reported a position in STLNW in Q1 2021 and held it in 4 quarters. The position peaked at $108K in Q2 2021. 12 funds tracked by Wall St. Rank hold STLNW as of Q1 2022.

  • Park West Asset Management reported no remaining Starling Oncology Warrant position as of Q1 2022 after selling out during the quarter.
  • Park West Asset Management sold 62,200 Starling Oncology Warrant shares in Q1 2022, an estimated $43K.
  • Park West Asset Management first reported a position in Starling Oncology Warrant in Q1 2021 and held it in 4 quarters.
  • Park West Asset Management's Starling Oncology Warrant position peaked at $108K in Q2 2021.
  • 12 funds tracked by Wall St. Rank held Starling Oncology Warrant as of Q1 2022.

Based on Park West Asset Management's 13F filing for Q1 2022, filed 16 May 2022.